

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Zylox-Tonbridge Medical Technology Co., Ltd.

歸創通橋醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2190)

VOLUNTARY ANNOUNCEMENT NATIONAL MEDICAL PRODUCTS ADMINISTRATION GRANTED MARKETING APPROVAL FOR TONBRIDGE QILIN™ FLOW DIVERTER

This announcement is made by Zylox-Tonbridge Medical Technology Co., Ltd. (the “**Company**”, together with its subsidiary, the “**Group**”) on a voluntary basis to provide the shareholders of the Company and potential investors with updated information in relation to the latest business and new product development of the Group.

The Company is pleased to announce that Tonbridge Qilin™ Flow Diverter, self-developed by the Group, has recently been granted marketing approval by the National Medical Products Administration (the “**NMPA**”). As the first visualized distal closure dense braided stent produced in China, Tonbridge Qilin™ Flow Diverter brings a new treatment option for intracranial aneurysm, while further enriching the Company’s product portfolio and strengthening its influence in the field of domestic neurovascular interventional treatment. As of the date of this announcement, the Company has obtained approvals from the NMPA for a total of 41 products in the People’s Republic of China (the “**PRC**”).

Flow diverter (FD) is a revolutionary product for the treatment of intracranial aneurysm. In recent years, it has become one of the most important options for the treatment of intracranial aneurysm, especially large or giant aneurysms. Tonbridge Qilin™ Flow Diverter is the first visualized distal closure dense braided stent produced in China, which is made of nitinol wrapped platinum material to achieve full visualization, with the closure design on the distal end. Compared with similar products in the market, Tonbridge Qilin™ Flow Diverter features better adherent and visualization performance, improving the visibility and safety during operations. At the same time, the more complete product models can meet the needs of different lesions in clinical treatment.

Among cerebrovascular diseases, the incidence rate of intracranial aneurysm is the third highest after cerebral thrombosis and hypertensive cerebral hemorrhage. It is estimated that there are more than 150,000 incidences of arterial aneurysms in the PRC. As disclosed in the Company's prospectus dated June 22, 2021, the number of intracranial aneurysm interventional procedures in the PRC is estimated to increase to 440,000 in 2030, at a CAGR of 19.9% from 2019 to 2030. With respect to large or giant intracranial aneurysms, the recurrence rate after stand-alone coil embolization or stent-assisted embolization of aneurysms is high. The development of flow diverter has reformed the treatment concept by altering the flow dynamics within the atheroma after placement in the diseased artery, slowing the formation of thrombus within the aneurysm, and enabling the meningothelium to climb onto the surface of the stent to reshape the vessel to repair the diseased carrier artery. Such new treatment has demonstrated tremendous market needs and growth potential. We estimate that the number of intracranial aneurysm procedures using flow diverter is expected to grow at a CAGR of 30% from 2019 to 2030. The marketing approval of Tonbridge Qilin™ Flow Diverter is the latest achievement that showcases the Company's commitment to developing differentiated and innovative products with real clinical value. In the future, the Company will continue to focus on the innovation in medical technology to bring more high-quality and affordable innovative medical devices to patients around the world.

By order of the board
Zylox-Tonbridge Medical Technology Co., Ltd.
Dr. Jonathon Zhong Zhao
Chairman and Executive Director

Hong Kong, March 25, 2024

As of the date of this announcement, the board of directors of the Company comprises Dr. Jonathon Zhong Zhao, Mr. Yang Xie and Dr. Zheng Li as executive directors, Mr. Stephen Hui Wang, Dr. Steven Dasong Wang and Mr. Dongfang Li as non-executive directors, and Dr. Jian Ji, Mr. Hongze Liang and Ms. Yun Qiu as independent non-executive directors.